Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet
- PMID: 38759140
- PMCID: PMC11175627
- DOI: 10.1212/WNL.0000000000209558
Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet
Conflict of interest statement
D.G. Di Luca has no disclosures; J.S. Perlmutter has served as Director of Medical and Scientific Advisory Committee of the Dystonia Medical Research Foundation, Chair of the Scientific Advisory Committee of the Parkinson Study Group (2020–2023), Chair of the Professional Ethics and Standards Committee of the Huntington Study Group, past member of the Scientific Advisory Board of the APDA (2016–2023), Chair of the Scientific and Publication Committee for ENROLL-HD (received honoraria), and is a member of the Education Committee of the Huntington Study Group (received honoraria), is an employee of Washington University in St. Louis, has received honoraria from CHDI, Huntington Study Group, Parkinson Study Group, Beth Israel Hospital (Harvard group), U Illinois in Chicago; Boston University, Georgetown University, St Lukes Hospital, has received payment for travel expenses from Dystonia Medical Research Foundation, is supported by the following NIH grants: NIH (NCATS, NINDS, NIA): NS103957, NS107281, RF1NS075321, RO1NS134586, RO1NS103957, NS097437, U54NS116025, U19 NS110456, NS097799, NS075527, ES029524, NS109487, R61 AT010753, RO1NS118146, UG3MH126861, NS124738, R01AG065214, NS124789, has received support from the Michael J Fox Foundation, Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), American Parkinson Disease Association (APDA) Advanced Research Center at Washington University, Missouri Chapter of the APDA, Paula and Rodger Riney Fund, Jo Oertli Fund, Huntington Disease Society of America, Murphy Fund, Fixel Foundation, N. Grant Williams Fund, Pohlman Fund, CHDI and Prilenia. He is also co-director for the Dystonia Coalition, which has received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke TR 001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences), and has provided medical-legal consultation regarding Parkinson disease in 2022 and tremor in 2023. Go to
Similar articles
-
Role of DAT-SPECT in diagnostic work-up of Parkinsonism.Mov Disord. 2008 Apr 15;23(5):774; author reply 774-5. doi: 10.1002/mds.21952. Mov Disord. 2008. PMID: 18265008 No abstract available.
-
Ethics of Preclinical Dopamine Transporter Imaging.Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1262-5. doi: 10.1212/CON.0000000000000351. Continuum (Minneap Minn). 2016. PMID: 27495208
-
Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism.Clin Nucl Med. 2018 Oct;43(10):710-714. doi: 10.1097/RLU.0000000000002240. Clin Nucl Med. 2018. PMID: 30153144
-
Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders.Turk J Med Sci. 2021 Apr 30;51(2):400-410. doi: 10.3906/sag-2008-253. Turk J Med Sci. 2021. PMID: 33237660 Free PMC article. Review.
-
The role of DAT-SPECT in movement disorders.J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. doi: 10.1136/jnnp.2008.157370. J Neurol Neurosurg Psychiatry. 2010. PMID: 20019219 Review.
Cited by
-
Nigrostriatal Degeneration Underpins Sensorimotor Dysfunction in an Inducible Mouse Model of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).Int J Mol Sci. 2025 Feb 11;26(4):1511. doi: 10.3390/ijms26041511. Int J Mol Sci. 2025. PMID: 40003975 Free PMC article.
-
Plasma acellular transcriptome contains Parkinson's disease signatures that can inform clinical diagnosis.medRxiv [Preprint]. 2024 Oct 18:2024.10.18.24315717. doi: 10.1101/2024.10.18.24315717. medRxiv. 2024. PMID: 39484251 Free PMC article. Preprint.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources